Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

fool.com - Jake Lerch - The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?
The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?
The Motley Fool –

Deciding between Invesco Pharmaceuticals ETF (PJP +0.25%) and iShares Global Healthcare ETF (IXJ +0.06%) involves choosing between a focused bet on U.S. drugmakers and broad exposure to global healthcare sectors. While both Invesco Pharmaceuticals…

fool.com - Brendan Coffey - Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?
Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?
The Motley Fool –

Investors choosing between Bristol Myers Squibb (BMY -1.57%) and Vertex Pharmaceuticals (VRTX +0.85%) must decide between a steady value play and a high-growth innovator as they look toward 2027. Bristol Myers Squibb operates as a diversified drug…

marketbeat.com - Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen
MarketBeat –

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a 'hold' rating to a 'buy' rating in a note issued to investors on Sunday, Wall Street Zen reports. Can BioMarin Stock Live Up to Wall…

rediff.com - Kairavi Lukka - Samvat 2082: Indian Markets Rebound, End Weakest Year in 15 on a High Note
Samvat 2082: Indian Markets Rebound, End Weakest Year in 15 on a High Note
Rediff.com –

Despite a challenging year marked by geopolitical tensions and foreign selling, Indian equity markets, including the Sensex and Nifty 50, staged a remarkable late recovery to end Samvat 2082 on a strong note, marking their weakest Samvat in 15…

fool.com - The Motley Fool Team - Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
The Motley Fool –

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Ginkgo Bioworks (DNA +13.35%) announced a strategic transition toward commercializing autonomous laboratory hardware and cloud data services. For long-term investors, this operational…

fool.com - Reuben Gregg Brewer - Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors
The Motley Fool –

Bristol Myers Squibb (BMY -1.57%) traces its history back to the mid-1800s. It is a proven survivor in the highly competitive and innovation-driven pharmaceutical sector. That can't save the company from the normal dynamics of the drug industry, as…

nextnewsnetwork.com - Gary Franchi - RFK Jr. Stands 'FIRMLY BEHIND' Trump as Democrats Demand He Resign
RFK Jr. Stands 'FIRMLY BEHIND' Trump as Democrats Demand He Resign
Next News Network –

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has made his position clear: he stands 'firmly behind' President Donald Trump and the 'historic reforms' the administration is advancing, according to a report from Breitbart. The…

straitstimes.com - Astellas employee jailed in China for espionage to be released in December: Japanese media
Astellas employee jailed in China for espionage to be released in December: Japanese media
The Straits Times –

Sign up now: Get insights on Asia's fast-moving developments Published Nov 08, 2026, 11:53 AM TOKYO - A Japanese employee of Astellas Pharma sentenced to three years and six months in prison for espionage in China is set to be released in…

redstate.com - Ward Clark - Former RFK Jr.-HHS Advisor Calley Means: Lobbyists Are Subverting Trump Administration's MAHA Agenda
Former RFK Jr.-HHS Advisor Calley Means: Lobbyists Are Subverting Trump Administration's MAHA Agenda
RedState –

Calley Means is an American health activist and entrepreneur, the founder of Truemed, a company that worked to enable tax-advantaged medical spending on health products. He also served as a senior adviser at the U.S. Department of Health and Human…

fool.com - Reuben Gregg Brewer - Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
The Motley Fool –

Eli Lilly (LLY -0.79%) is much loved on Wall Street because of its highly successful GLP-1 weight-loss business. Novo Nordisk (NVO +0.03%) is much less appreciated because it lost the GLP-1 lead to Eli Lilly. But they aren't the only companies…

thehindubusinessline.com - BL Mumbai Bureau - Revised prices on anti-cancer medicines effective from Monday, estimated annual savings of over ₹3500 crore
Revised prices on anti-cancer medicines effective from Monday, estimated annual savings of over ₹3500 crore
The HinduBusinessLine –

Giving the latest update, the NPPA said on Saturday, about 76 pharmaceutical companies have revised MRPs for 1225 anti-cancer formulations, covering 121 drugs. A reduction has been reported in 1031 formulations of anti-cancer medicines, with 600…

newtimes.co.rw - Frank Ntarindwa - Forty companies, individuals honoured at 10th Karisimbi Service Excellence Awards
Forty companies, individuals honoured at 10th Karisimbi Service Excellence Awards
The New Times –

Rwanda's drive to strengthen its competitiveness as a destination for tourism, investment and business requires companies and institutions to deliver quality services and better customer experiences, Karisimbi Events Chief Executive Emmanuel…

singularityhub.com - SingularityHub Staff - This Week's Awesome Tech Stories From Around the Web (Through November 7)
This Week's Awesome Tech Stories From Around the Web (Through November 7)
Home | SingularityHub –

Every week, we scour the web for important, insightful, and fascinating stories in science and technology. The Smartest People in AI Believe This Is the World's Most Important Chart Ben Cohen | The Wall Street Journal ($) 'Anthropic refers to…

takecontrol.substack.com - Top Supplements Americans Use Are Shifting from Multivitamins to Targeted Health Fixes
Top Supplements Americans Use Are Shifting from Multivitamins to Targeted Health Fixes
Dr. Mercola's Censored Library (Private Membership) –

After more than two decades of data, a clear shift has emerged in how people choose their nutrients, with adults over 65 leading the change. This is your last chance to get these Early Black Friday savings! Enjoy savings on featured products and…

thehindubusinessline.com - Kumar Shankar Roy - Can Samvat 2083 sustain the rebound?
Can Samvat 2083 sustain the rebound?
The HinduBusinessLine –

Can the next Samvat sustain the recovery? History offers hope, but geopolitical tensions, AI bubble concerns, elevated global bond yields and stretched domestic valuations pose risks. domestic valuations pose risks. An analysis by bl.portfolio of…

Receive a Daily briefing on Pharma Industry News

Get Started